Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial
Publication
, Conference
Schlenk, RF; Montesinos, P; Romero-Aguilar, A; Vrhovac, R; Patkowska, E; Kim, H-J; Zak, P; Wang, P-N; Hanyok, J; Liu, L; Kamel, YM; Cortes, J ...
Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
2023
Duke Scholars
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
2023
Volume
23
Start / End Page
S521 / S522
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Schlenk, R. F., Montesinos, P., Romero-Aguilar, A., Vrhovac, R., Patkowska, E., Kim, H.-J., … Erba, H. P. (2023). Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 23, pp. S521–S522).
Schlenk, Richard F., Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elzbieta Patkowska, Hee-Je Kim, Pavel Zak, et al. “Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 23:S521–22, 2023.
Schlenk RF, Montesinos P, Romero-Aguilar A, Vrhovac R, Patkowska E, Kim H-J, et al. Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023. p. S521–2.
Schlenk, Richard F., et al. “Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 23, 2023, pp. S521–22.
Schlenk RF, Montesinos P, Romero-Aguilar A, Vrhovac R, Patkowska E, Kim H-J, Zak P, Wang P-N, Hanyok J, Liu L, Kamel YM, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Perl AE, Levis MJ, Erba HP. Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023. p. S521–S522.
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
2023
Volume
23
Start / End Page
S521 / S522
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences